11/13
10:08 am
svra
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its price target lowered by analysts at HC Wainwright from $10.00 to $6.00. They now have a "buy" rating on the stock.
11/13
08:20 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences [Yahoo! Finance]
11/13
08:05 am
svra
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
High
Report
Savara Inc (NASDAQ: SVRA) had its "in-line" rating re-affirmed by analysts at Evercore ISI. They now have a $5.00 price target on the stock, down previously from $7.00.
11/13
08:05 am
svra
Savara Announces Participation in Upcoming Healthcare Conferences
High
Report
Savara Announces Participation in Upcoming Healthcare Conferences
11/12
08:05 am
svra
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Savara Reports Third Quarter 2024 Financial Results and Provides Business Update
11/4
04:24 pm
svra
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference [Yahoo! Finance]
Low
Report
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference [Yahoo! Finance]
11/4
04:05 pm
svra
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
Low
Report
Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/22
08:05 am
svra
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
Medium
Report
Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of “The Balancing Act®” Airing on Lifetime® TV
10/18
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Low
Report
Savara Announces New Employment Inducement Grant
10/8
08:45 am
svra
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/1
10:05 am
svra
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
10/1
08:05 am
svra
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
Medium
Report
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
10/1
08:01 am
svra
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
9/27
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Neutral
Report
Savara Announces New Employment Inducement Grant
9/27
08:11 am
svra
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
Low
Report
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) [Yahoo! Finance]
9/27
08:05 am
svra
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Low
Report
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
9/24
08:05 am
svra
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
Medium
Report
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
9/23
08:12 am
svra
Savara to Host Analyst and Investor Webinar on September 30, 2024 [Yahoo! Finance]
Low
Report
Savara to Host Analyst and Investor Webinar on September 30, 2024 [Yahoo! Finance]
9/23
08:05 am
svra
Savara to Host Analyst and Investor Webinar on September 30, 2024
Medium
Report
Savara to Host Analyst and Investor Webinar on September 30, 2024
9/9
07:08 pm
svra
Savara: Trial Successful, But I'm Only Half Convinced [Seeking Alpha]
Low
Report
Savara: Trial Successful, But I'm Only Half Convinced [Seeking Alpha]
9/9
11:05 am
svra
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
Medium
Report
Savara Inc (NASDAQ: SVRA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $9.00 price target on the stock.
9/8
06:49 am
svra
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 [Yahoo
Medium
Report
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024 [Yahoo
9/8
06:45 am
svra
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Medium
Report
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
9/6
04:05 pm
svra
Savara Announces New Employment Inducement Grant
Medium
Report
Savara Announces New Employment Inducement Grant
9/3
04:05 pm
svra
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference